1 / 57

Urinary Incontinence

Urinary Incontinence. Mixed. Urge. Stress. Jan Busby-Whitehead , MD Chief, Division of Geriatric Medicine University of North Carolina. Definition of Urinary Incontinence. “ The involuntary loss of urine which is objectively demonstrable and a social or hygienic problem.”.

taylor
Download Presentation

Urinary Incontinence

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Urinary Incontinence Mixed Urge Stress Jan Busby-Whitehead, MD Chief, Division of Geriatric Medicine University of North Carolina

  2. Definition of Urinary Incontinence “The involuntary loss of urine which is objectively demonstrable and a social or hygienic problem.” * The International Continence Society

  3. URINARY INCONTINENCE University of North Carolina School of Medicine Center for Aging and Health

  4. Prevalence • Community: 17% older men, up to 30% older women • Hospital: up to 50% older men and women • LTCF: 50-70% older men and women

  5. Prevalence of Incontinence in Women Hunskaar, et.al., IntUrogynecol J, 2000

  6. Prevalence of Incontinencein Community-Dwelling Women Hunskaar, et.al., Int Urogynecol J, 2000

  7. Reversible causes of UI D - Delirium or Drugs - Restricted mobility - Infection, impaction - Polyuria R I P

  8. Drugs Contributing to UI

  9. Bladder Anatomy • Hollow, distensible, muscula organ • Reservoir of urine • Capacity ~600 mL • Desire ~200 mL • Normal void ~300 mL • Organ of excretion • Behind symphysis pubis • Female – against anterior wall of uterus • Trigone • Sphincter

  10. Physiology

  11. Aging Changes • Decreased bladder capacity • Reduced voiding volume • Reduced flow rates • Increased urine production at night • * Nordling, J Experimental Gerontology, 2002, 37:991

  12. University of North Carolina School of Medicine Center for Aging and Health

  13. Stress UI Abrams P et al. Urology. 2003;61:37-49. The complaint of involuntary leakage with effort or exertion or on sneezing or coughing Sudden increase in abdominal pressure Urethral pressure

  14. Involuntary detrusor contractions Urethral pressure Urge UI Abrams P et al. Urology. 2003;61:37-49. Ouslander J. N Engl J Med. 2004;350(8):786-799. • The complaint of involuntary leakage accompanied by or immediately preceded by urgency

  15. Overactive bladder • Includes urinary urgency with or without urge incontinence, urinary frequency, and nocturia • Associated with involuntary contractions of the detrusor muscle

  16. Sudden increase in abdominal pressure Involuntary detrusor contractions Urethral pressure Mixed UI Abrams P et al. Urology. 2003;61:37-49. Chaliha C et al. Urology. 2004;63:51-57. The complaint of involuntary leakage associated with urgency and also with exertion, effort, sneezing, or coughing

  17. Overflow • Urethral blockage • The Bladder is not able • to empty properly Neurogenic/Atonic Obstruction

  18. Functional Incontinence • Immobility • Diminished vision • Aphasia • Environment • Psychological

  19. Clinical Questions • How do you evaluate for incontinence? • Are behavioral techniques effective? For which patients? • What drug treatments are useful and how do you use them?

  20. Office Evaluation of UI • Identify presence of UI • Assess for reversible causes and treat • If UI persistent, determine type and initiate treatment • Identify patient who needs further evaluation and referral

  21. Basic Evaluation of UI • History: Bladder diary • Physical examination, especially Genitourinary and Neurological • Bladder stress test • Postvoid residual • Urinalysis, urine culture if indicated • BUN, creatinine, fasting glucose

  22. Referral Criteria • Recurrent urinary tract infections • Hematuria • Elevated postvoid residual or other evidence of possible obstruction • Recent gynecological or urological surgery or pelvic radiation • Failed treatment of stress or urge UI

  23. Cystometry • Gold standard for diagnosis • New definition for detrusor overactivity: Any rise in detrusor pressure during filling cystometry associated with symptoms and not related to abnormal bladder compliance • Provocative stimuli • Ambulatory monitoring

  24. Treatment Options • Behavioral • Pharmacological • Functional Electrical Stimulation • Surgery

  25. Are behavioral techniques effective? For whom? • Behavioral techniques are effective for treatment of stress and urge UI, and overactive bladder, but generally do not cure • Behavioral techniques are effective in community dwelling men and women • Behavioral techniques are most appropriate for cognitively intact, motivated persons

  26. Behavioral Treatments for UI University of North Carolina School of Medicine Center for Aging and Health

  27. Self Management • Fluid Intake • Don’t reduce amount • Do not drink fluids 2 hr before bedtime • Avoid: caffeine, alcohol, nicotine

  28. Scheduled Voiding • Scheduled voiding with systematic delay of voiding • Schedule based on time interval pt can manage in daytime • Void at scheduled time even if urge not present; suppress urge if not time with “Quick Kegels” • Increase voiding interval by 30 min each week until continent for up to 4 hr

  29. Pelvic Muscle Exercises • Isolation of the pelvic muscles • Avoidance of abdominal, buttock or thigh muscle contractions • Moderate repetitions of strongest contraction possible • Ability to hold contraction 10 seconds, repeat in groups of 10-30 TID

  30. Efficacy of Behavioral Treatment PMFE Without Biofeedback PMFE With Biofeedback 100 90 80 70 60 50 40 30 20 10 0 98% 91% 50% 38% Range of Improvement Range of Improvement

  31. Randomized Trials of Behavioral Treatment for Stress UI • 24 RCTs, but only 11 of high quality • Pelvic floor exercises were effective (up to 75%)in reducing symptoms of stress UI • Limited evidence for high vs low intensity • Benefits of adding biofeedback unclear * Berghmans et al. Br J Urol 1998:82:181-191

  32. Behavioral Treatment for Urge/OAB • Bladder training • Initial approach • 3 RCT: 47-90% cure rate with 6 mo f/u • Recurrence in 43-58% after 2-3 yr • 35% fewer UI episodes vs controls: Cochrane Review 2004

  33. Limitations of Behavioral Treatment Studies • Studies varied in • types of UI • characteristics of subjects • intervention strategies • outcome measures used • duration of follow-up • Few studies compared the efficacy of PFME performed with and without biofeedback

  34. NIH Treatment Trial Kincade, Dougherty, Busby-Whitehead Purpose: • Compare pelvic floor muscle exercises alone to PFME plus biofeedback in women with stress and mixed urge and stress UI • Design • 315 women randomized to 3 groups, including an attention control group • Followup up at 2 weeks, 6 months, 1 year

  35. Drug Treatment for UI: What Works • Stress UI • Alpha adrenergic agents? • Estrogen? • Combination therapy?

  36. Alpha Adrenergic Drugs • Phenylpropanoloamine • Once a first line drug • 8 randomized controlled trials • Study duration: 2-6 weeks • % cure: 0-14 • % side effects: 5-33% • WITHDRAWN FROM MARKET due to report of hemorrhagic stroke

  37. Duloxetine(Cymbalta) • FDA application for stress UI withdrawn • Warning for liver dysfunction, alcohol

  38. Estrogen • Combined study with Phenylpropanolamine suggested improvement in combination • Improves urogenital atrophy • Heart and Estrogen/Progestin Replacement Study 2001: 4 yr, randomized trial, 2763 postmenopausal women <80 given combined HRT or placebo for ischemic heart disease. • 55% had >1 episode UI/week • HRT group had worsening stress and urge UI sx

  39. Drug Treatment of Overactive Bladder • Anticholinergic Drugs are mainstay • Oxybutynin IR 2.5-5 mg bid-qid • Ditropan XL 5-20 mg daily • Oxytrol patch TDS 3.9 mg 2x/wk • Tolterodinetartrate IR 1-2 mg bid • Detrol LA 2-4 mg daily New Drugs: • Trospium chloride (Sanctura) 20 mg bid • Darifenicin (Enablex) 7.5-15 mg daily • Solefenicin (Vesicare) 5-10 mg daily

  40. Muscarinic Receptors • M1 – Brain (cortex, hippocampus), salivary • glands, sympathetic ganglia • M2 – Heart, hindbrain, smooth muscle (80% of detrusor) • M3 – Smooth muscle (20% of detrusor), salivary glands, brain, eye (lens, iris) • M4 – Brain (forebrain, striatum) • M5 – Brain (substantianigra), eye

  41. Hepatic metabolism • Oxybutynin CYP 3A4 • Tolterodine CYP 3A4, CYP 2D6 • Darifenacin CYP 3A4, CYP 2D6 • Solifenacin CYP 3A4 • CYP 3A4: Interactions with macrolides, ketoconazole, nefazadone • CYP 2D6: interactions with TCAs, fluoxetine

  42. Behavioral vs Drug Rx for Urge UI in Older Women • Randomized, controlled trial by Burgio et al JAMA 1998; 280; 1995-2000 • 197 women aged 55-92 • 8 weeks of BFB, 8 weeks of oxybutynin • 2.5 to 5 mg qd to tid, or placebo control • All 3 groups reduced UI frequency • Effectiveness: BFB>drug>placebo

  43. Burgio et al JAMA 1998; 280:1995-2000 Oxybutyninvs Behavioral Treatment for Urge UI

  44. Oxybutynin • Both anticholinergic and smooth muscle relaxant properties • 6/7 RCTs show benefit • 15-58% greater reduction in urge UI than placebo • Dose: 2.5 -5 mg qd-qid, 20 mg/d maximum

  45. Oxybutynin Controlled Release • Once daily dosing • RCT showed rate of daytime continence similar to that for immediate release (53 vs 58%) • Lower rate of dry mouth than immediate release form

  46. Tolterodinetartrate • Pure muscarinic receptor antagonist • Dry mouth most common side effect • 3 RCT compared tolterodine (2 mg bid) to oxybutynin (5 mg tid): Equally effective and superior to placebo • Decreased urge U(I in study of 293 pts:47% tolterodine, 71% oxybutynin, 19% placebo, dry mouth 86% oxybutynin, 50% tolerodine

  47. OBJECT Study Appel et al Mayo Clin Proc 2001:76 • Compared efficacy and tolerability of extended release oxybutynin and tolterodine tartrate • 12 weeks • Prospective randomized,double-blind, parallel group study • 276 women and 56 men • Oxybutynin more effective for weekly urge UI, total incontinence, and urinary frequency

  48. Trospium • Dose 20 mg bid • Renal metabolism • Nonselective for muscarinic receptors • Effective for detrusoroveractivity in placebo-controlled double-blind studies: • Trospium 20 mg bid vstolterodine 2 mg bid in 232 pts reduced voiding frequency and number of UI episodes • Dry mouth 7% and 9% respectively

  49. Darifenicin • Dose 7.5 to 15 mg daily • Selective M3 receptor antagonist • Several RCTs • Mundy et al 2001 Randomized double-blind trial compared darifenacin 15 mg and 30 mg to oxybutynin 5 mg tid in 25 pts , similar efficacy • Side effects: Dry mouth, constipation(<2%)

  50. Solefenacin • Dose 5 to 10 mg daily • Long acting muscarinic receptor antagonist, selective for M3 • Undergoes hepatic metabolism involving cytochrom P450 • Several multinational trials with over 800 pts, vs placebo, showed efficacy low side effects (2% dry mouth)

More Related